LAVAL, QC, April 24 /CNW/ - BioSyntech, Inc. (“BioSyntech” or “the Company”) (TSX: BSY), a biotechnology company developing novel products in regenerative medicine, today announced that its abstract summarizing the safety and effectiveness of BST-DermOn(TM) in promoting the healing of various types of chronic wounds that have failed previous treatments, has been selected for poster presentation at The 3rd Congress of the World Union of Wound Healing Societies (WUWHS). The abstract is entitled “Interim Pilot Study Results of a Chitosan-Based Hydrogel (BST-DermOn(TM)) in the Treatment of Chronic Wounds”. Results of this open, non-controlled study will be presented in a poster authored by Dr. Gary Sibbald, a world-renowned dermatologist and recognized leader in the field of wound care, and the Principal Investigator of the Company’s BST-DermOn(TM) pivotal trial. The WUWHS Congress will be held in Toronto, Ontario, from June 4 - 8, 2008.
